Skip to main content
ASSURE TECH (HANGZHOU) CO., LTD. logo

ASSURE TECH (HANGZHOU) CO., LTD. — Investor Relations & Filings

Ticker · 688075 ISIN · CNE100004ZC0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 449 across all filing types
Latest filing 2026-04-29 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688075

About ASSURE TECH (HANGZHOU) CO., LTD.

https://www.diareagent.com/

Assure Tech (Hangzhou) Co., Ltd. is a biotechnology enterprise specializing in the research, development, and manufacturing of in vitro diagnostic (IVD) reagents and clinical testing instruments. The company focuses on rapid diagnostic tests and Point of Care Testing (POCT) solutions across various medical fields, including infectious diseases, drug of abuse screening, oncology, cardiac markers, and fertility. Utilizing advanced lateral flow immunoassay technology, Assure Tech provides diagnostic tools designed for accuracy and efficiency in clinical and laboratory settings. The company adheres to international quality standards, maintaining ISO 13485 certification and obtaining regulatory clearances such as FDA and CE marks for its product range. Through its integrated R&D and production infrastructure, Assure Tech supplies a diverse portfolio of diagnostic products to a global customer base.

Recent filings

Filing Released Lang Actions
安旭生物2025年度独立董事述职报告（马卫民已离任）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Work Report" for the year 2025 from Hangzhou Anxu Biotechnology Co., Ltd. It details the independent director's background, attendance at board and committee meetings, communication with auditors, oversight of financial reports, and other governance-related activities during the director's term. The content focuses on the director's duties, evaluations, and governance oversight rather than presenting financial statements or audit opinions. The document length is 4105 characters, which is relatively short and consistent with a report or statement rather than a full financial report. It is not an announcement of a report publication but a substantive report on the independent director's work and governance role. This fits best under the category of Board/Management Information (MANG), which includes announcements related to board members and senior management activities, including independent directors' reports and evaluations.
2026-04-29 Chinese
安旭生物2025年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2025年度内部控制评价报告' which translates to '2025 Internal Control Evaluation Report'. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2025, including financial and non-financial internal control defects, their identification, and rectification status. The document includes detailed internal control standards, scope, and conclusions about the effectiveness of internal controls. It is a standalone report focused on internal control evaluation rather than a full annual report or audit report. The content aligns with an Audit Report / Information filing, as it provides results of internal control evaluations and related audit opinions, but is not a full annual report (10-K) or interim report. The document length is 4061 characters, which is sufficient for a detailed report but not a brief announcement. Therefore, the appropriate classification is AR (Audit Report / Information). FY 2025
2026-04-29 Chinese
安旭生物董事会审计委员会2025年度履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled as a "Board Audit Committee 2025 Annual Performance Report" from Hangzhou Anxu Biotechnology Co., Ltd. It details the audit committee's activities, meetings, oversight of external and internal audits, review of financial reports for 2024 and 2025 quarterly periods, and internal control supervision. The content focuses on the audit committee's supervisory and evaluative role rather than presenting full financial statements or detailed financial data. It is a report on the audit committee's duties and performance rather than a standalone audit report or full annual report. The document length is 2352 characters, which is relatively short and more consistent with a committee report rather than a full audit report. Therefore, the document fits best under the category of Audit Report / Information (AR), which includes standalone audit reports and related committee reports on audit activities, excluding full annual reports. FY 2025
2026-04-29 Chinese
安旭生物关于以集中竞价交易方式首次回购公司股份的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Hangzhou Anxu Biotechnology Co., Ltd. regarding the company's initial share repurchase through centralized bidding. It details the repurchase plan, progress, amounts, prices, and regulatory compliance. The content focuses on the company's buyback of its own shares, including specifics such as repurchase amount, price range, and purpose (employee stock plans or equity incentives). There is no indication of financial results, management discussion, or other report types. The document length is short (1278 characters) and is a formal announcement of share repurchase activity, fitting the definition of Transaction in Own Shares (POS).
2026-04-16 Chinese
安旭生物关于以集中竞价交易方式回购股份的回购报告书
Transaction in Own Shares Classification · 100% confidence The document is a detailed announcement regarding a company's plan to repurchase its own shares through centralized bidding. It includes specifics such as the amount of funds allocated, the price limits, the purpose of the repurchase (employee stock ownership plan or equity incentives), the timeline, and the authorization process. It also discusses risks, regulatory compliance, and the impact on the company's financials and share structure. The content is focused on the share repurchase plan and its implementation rather than financial results or management changes. This matches the definition of a Transaction in Own Shares (POS) filing, which covers company buyback or sale of its own shares. The document length and detail confirm it is the actual report of the repurchase plan, not just an announcement of a report publication or a brief notice.
2026-04-03 Chinese
安旭生物关于回购股份事项前十名股东和前十名无限售条件股东持股情况的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement from Hangzhou Anxu Biotechnology Co., Ltd. regarding the top ten shareholders and top ten unrestricted shareholders as of a specific date (March 31, 2026) in relation to a share repurchase plan approved on March 30, 2026. It references a previous announcement about the share repurchase plan and provides detailed shareholding data. The document is short (1347 characters) and focuses on shareholder holdings related to a share buyback. This fits the category of a Transaction in Own Shares (POS) filing, which covers company buyback or sale of its own shares. There is no indication this is a full financial report, regulatory filing, or other types of announcements. Therefore, the classification is POS with high confidence.
2026-04-02 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.